ArticleEndocrine connections2026
Circulating Apelin-13, β-catenin and bone mineral density in postmenopausal women.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
abstractThe aim of this study was to investigate associations of circulating Apelin-13, β-catenin, Exendin-4, and Nesfatin-1 with site-specific bone mineral density (BMD) in postmenopausal women, representing adipose-endocrine, Wnt/β-catenin, incretin-related, and energy homeostasis pathways. A total of 315 postmenopausal women were classified into normal bone mass, osteopenia, or osteoporosis group according to World Health Organization criteria using dual-energy X-ray absorptiometry. Serum biomarkers were measured by enzyme-linked immunosorbent assay. Lumbar spine BMD and hip BMD were analyzed separately using group comparisons, Spearman correlation, fully adjusted multivariable linear regression, and exploratory receiver operating characteristic (ROC) analyses. Lumbar spine BMD was 0.936 ± 0.084, 0.935 ± 0.121, and 0.741 ± 0.105 g/cm2 in the normal bone mass, osteopenia, and osteoporosis groups, respectively; hip BMD was 0.942 ± 0.045, 0.878 ± 0.073, and 0.702 ± 0.084 g/cm2. Apelin-13 decreased across groups from 702.09 ± 56.42 to 624.98 ± 43.99 and 334.37 ± 91.49 pg/mL, and β-catenin from 100.23 ± 11.34 to 76.21 ± 14.65 and 54.33 ± 8.25 ng/mL. In fully adjusted models, Apelin-13 was independently associated with lumbar spine BMD (β = 0.547, P < 0.001) and hip BMD (β = 0.524, P < 0.001), while β-catenin was associated with hip BMD (β = 0.272, P < 0.001). Exploratory ROC analyses suggested apparent discriminatory performance for Apelin-13, β-catenin, Nesfatin-1, Exendin-4, and the combined model, with AUCs of 1.000, 0.944, 0.680, 0.613, and 1.000, respectively; these findings should be interpreted cautiously and require external validation. Apelin-13 and β-catenin may serve as circulating biomarkers related to site-specific bone mass status, requiring external validation. ENDOCRINE CONNECTIONS: Bone loss is common in women after menopause, yet blood-based markers that reflect bone health remain limited. In this study, we measured four circulating biomarkers related to metabolic and bone regulatory pathways and compared them with BMD. Women with higher BMD generally had higher levels of Apelin-13 and β-catenin, and these two biomarkers showed the strongest associations with bone mass. These findings suggest that circulating biomarkers may provide additional information about bone mass status, but further validation in independent populations is needed before clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.